Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis

Sun Yat-sen University150 enrolled

Overview

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.

To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein. We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Portal Vein, Cavernous Transformation Of

Interventions

MontelukastDRUG

Montelukast (10mg, q.d., p.o.)

Eligibility

Sex: ALLMin age: 1 YearMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients with CTPV. Exclusion Criteria: * Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.

Locations (1)

Department of Radiology

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Ascites Volume (mL)

Ascites measured by CT scanning or ultrasound (If the patients had the history of ascites before)

Time frame: 6 month

Hydrothorax Volume (mL)

Hydrothorax measured by CT scanning or ultrasound (If the patients had the history of hydrothorax before)

Time frame: 6 month

Central Contacts

Zaibo Jiang, MD

CONTACT

+86 020 85253416 jiangzaibo@aliyun.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.